FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616448563> ?p ?o ?g. }

• W2616448563 endingPage "79314" @default.
• W2616448563 startingPage "79305" @default.
• W2616448563 abstract "// Liheng Zhou 1 , Shuguang Xu 1 , Wenjin Yin 2 , Yanpin Lin 1 , Yueyao Du 1 , Yiwei Jiang 1 , Yaohui Wang 1 , Jie Zhang 1 , Ziping Wu 1 and Jinsong Lu 1 1 Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China 2 Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China Correspondence to: Jinsong Lu, email: // Keywords : cisplatin, paclitaxel, breast cancer, neoadjuvant, biomarker Received : February 17, 2017 Accepted : May 05, 2017 Published : May 17, 2017 Abstract There was little evidence of weekly cisplatin regimen either for the locally advanced breast cancer or the metastatic setting. We aimed to evaluate that whether the combination of weekly paclitaxel and cisplatin could improve the efficacy of the neoadjuvant treatment for patients with locally advanced breast cancer. Patients with histologically confirmed large operable breast cancer received paclitaxel 80mg/m 2 by weekly for 16 weeks and weekly cisplatin 25mg/m 2 on day 1, 8 and 15, out of every 28 days for 4-week cycles. Trastuzumab was allowed for HER2-positive disease as weekly continuous regimen. The primary endpoint was locoregional total pathological complete response (tpCR) in breast and axilla lymph nodes after neoadjuvant treatment. One hundred and thirty-one patients were included in the study, among which 34.4% (45/131) patients achieved tpCR. Rate of pathological complete response (pCR) in the breast was 44.3% and the rate of near-pCR in breast was 48.1%. A significantly higher proportion of tpCR was seen in patients with triple negative breast cancer (64.7%, p = 0.003) and HER2 positive (non-luminal) cancer (52.4%, p = 0.018) compared with those who had luminal type tumors (24.7%). At multivariate analysis, negative estrogen receptor and high ki67 level independently predicted a better response. The most frequent toxicities were anemia, leukopenia and peripheral sensory neuropathy. Neoadjuvant chemotherapy by weekly paclitaxel and cisplatin combination was highly effective and tolerated in this study, especially in the triple negative and HER2 positive tumors." @default.
• W2616448563 created "2017-05-26" @default.
• W2616448563 creator A5006099817 @default.
• W2616448563 creator A5035480324 @default.
• W2616448563 creator A5036843473 @default.
• W2616448563 creator A5041558510 @default.
• W2616448563 creator A5074669391 @default.
• W2616448563 creator A5077679983 @default.
• W2616448563 creator A5077702921 @default.
• W2616448563 creator A5082102216 @default.
• W2616448563 creator A5085509317 @default.
• W2616448563 creator A5088039838 @default.
• W2616448563 date "2017-05-17" @default.
• W2616448563 modified "2023-09-26" @default.
• W2616448563 title "Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study" @default.
• W2616448563 cites W1991584640 @default.
• W2616448563 cites W2007648830 @default.
• W2616448563 cites W2014179352 @default.
• W2616448563 cites W2020724013 @default.
• W2616448563 cites W2074758119 @default.
• W2616448563 cites W2075894019 @default.
• W2616448563 cites W2076139950 @default.
• W2616448563 cites W2077396057 @default.
• W2616448563 cites W2096745115 @default.
• W2616448563 cites W2101156795 @default.
• W2616448563 cites W2105496345 @default.
• W2616448563 cites W2114710110 @default.
• W2616448563 cites W2132387160 @default.
• W2616448563 cites W2134012086 @default.
• W2616448563 cites W2142486051 @default.
• W2616448563 cites W2146165949 @default.
• W2616448563 cites W2146717458 @default.
• W2616448563 cites W2155808778 @default.
• W2616448563 cites W2162760540 @default.
• W2616448563 cites W2173858545 @default.
• W2616448563 doi "https://doi.org/10.18632/oncotarget.17954" @default.
• W2616448563 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5668042" @default.
• W2616448563 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29108309" @default.
• W2616448563 hasPublicationYear "2017" @default.
• W2616448563 type Work @default.
• W2616448563 sameAs 2616448563 @default.
• W2616448563 citedByCount "24" @default.
• W2616448563 countsByYear W26164485632018 @default.
• W2616448563 countsByYear W26164485632019 @default.
• W2616448563 countsByYear W26164485632020 @default.
• W2616448563 countsByYear W26164485632021 @default.
• W2616448563 countsByYear W26164485632022 @default.
• W2616448563 crossrefType "journal-article" @default.
• W2616448563 hasAuthorship W2616448563A5006099817 @default.
• W2616448563 hasAuthorship W2616448563A5035480324 @default.
• W2616448563 hasAuthorship W2616448563A5036843473 @default.
• W2616448563 hasAuthorship W2616448563A5041558510 @default.
• W2616448563 hasAuthorship W2616448563A5074669391 @default.
• W2616448563 hasAuthorship W2616448563A5077679983 @default.
• W2616448563 hasAuthorship W2616448563A5077702921 @default.
• W2616448563 hasAuthorship W2616448563A5082102216 @default.
• W2616448563 hasAuthorship W2616448563A5085509317 @default.
• W2616448563 hasAuthorship W2616448563A5088039838 @default.
• W2616448563 hasBestOaLocation W26164485631 @default.
• W2616448563 hasConcept C121608353 @default.
• W2616448563 hasConcept C126322002 @default.
• W2616448563 hasConcept C143998085 @default.
• W2616448563 hasConcept C203092338 @default.
• W2616448563 hasConcept C2776608951 @default.
• W2616448563 hasConcept C2776694085 @default.
• W2616448563 hasConcept C2777292972 @default.
• W2616448563 hasConcept C2778239845 @default.
• W2616448563 hasConcept C2778292576 @default.
• W2616448563 hasConcept C2781413609 @default.
• W2616448563 hasConcept C530470458 @default.
• W2616448563 hasConcept C535046627 @default.
• W2616448563 hasConcept C71924100 @default.
• W2616448563 hasConceptScore W2616448563C121608353 @default.
• W2616448563 hasConceptScore W2616448563C126322002 @default.
• W2616448563 hasConceptScore W2616448563C143998085 @default.
• W2616448563 hasConceptScore W2616448563C203092338 @default.
• W2616448563 hasConceptScore W2616448563C2776608951 @default.
• W2616448563 hasConceptScore W2616448563C2776694085 @default.
• W2616448563 hasConceptScore W2616448563C2777292972 @default.
• W2616448563 hasConceptScore W2616448563C2778239845 @default.
• W2616448563 hasConceptScore W2616448563C2778292576 @default.
• W2616448563 hasConceptScore W2616448563C2781413609 @default.
• W2616448563 hasConceptScore W2616448563C530470458 @default.
• W2616448563 hasConceptScore W2616448563C535046627 @default.
• W2616448563 hasConceptScore W2616448563C71924100 @default.
• W2616448563 hasIssue "45" @default.
• W2616448563 hasLocation W26164485631 @default.
• W2616448563 hasLocation W26164485632 @default.
• W2616448563 hasLocation W26164485633 @default.
• W2616448563 hasLocation W26164485634 @default.
• W2616448563 hasOpenAccess W2616448563 @default.
• W2616448563 hasPrimaryLocation W26164485631 @default.
• W2616448563 hasRelatedWork W1255356622 @default.
• W2616448563 hasRelatedWork W2055272681 @default.
• W2616448563 hasRelatedWork W2100029565 @default.
• W2616448563 hasRelatedWork W2187491254 @default.
• W2616448563 hasRelatedWork W2367105124 @default.
• W2616448563 hasRelatedWork W2388730008 @default.

• next